Scinai Immunotherapeutics Appoints Eran Kuratz to Lead CDMO Supply Chain Operations

Scinai Immunotherapeutics has appointed Eran Kuratz to head supply chain and business process administration for its CDMO subsidiary, a move that strengthens its operational capabilities as it expands its contract manufacturing platform.

NY Metrowire Staff
Healthcare
Scinai Immunotherapeutics Appoints Eran Kuratz to Lead CDMO Supply Chain Operations

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. Kuratz brings more than 30 years of leadership and operational experience across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes.

The appointment comes as Scinai expands its contract development and manufacturing organization (CDMO) platform through the first-quarter 2026 acquisition of Recipharm Israel, which added a second development and manufacturing site in Yavne. Combined with Scinai's Jerusalem operations, the expanded platform now provides capabilities spanning biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing. This strategic expansion positions Scinai to offer a broader range of services to its clients.

Kuratz's extensive background in supply chain management and business process optimization is expected to be instrumental in integrating the new Yavne facility and streamlining operations across both sites. His appointment underscores Scinai's commitment to operational excellence and its focus on meeting the growing demand for CDMO services in the biopharmaceutical industry.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. Additionally, Scinai owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through its facilities in Jerusalem and Yavne, Israel.

This move is part of Scinai's broader strategy to enhance its service offerings and operational efficiency. By bringing in a seasoned executive like Kuratz, the company aims to strengthen its supply chain resilience and business process management, which are critical for maintaining high-quality manufacturing standards and meeting client expectations.

For more details on Scinai's latest developments, visit the company's newsroom at Scinai Newsroom. The full press release about this appointment can be viewed at Press Release.

Blockchain Registration

QR Code for Blockchain Registration